The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).
V. Guarneri
No relevant relationships to disclose
A. Frassoldati
No relevant relationships to disclose
A. Bottini
No relevant relationships to disclose
D. G. Generali
No relevant relationships to disclose
K. Cagossi
No relevant relationships to disclose
F. Artioli
No relevant relationships to disclose
G. Bisagni
No relevant relationships to disclose
C. Boni
No relevant relationships to disclose
A. Ravaioli
No relevant relationships to disclose
D. Amadori
No relevant relationships to disclose
A. Musolino
No relevant relationships to disclose
L. Cavanna
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose
L. Orlando
No relevant relationships to disclose
G. Giardina
No relevant relationships to disclose
F. Piacentini
No relevant relationships to disclose
E. Tagliafico
No relevant relationships to disclose
M. Bagnalasta
Employment or Leadership Position - GlaxoSmithKline
R. D'Amico
No relevant relationships to disclose
P. F. Conte
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline